Ociperlimab
drugOn this page
Also known as Bgb-a1217BGBA-1217BGBA1217
Summary
Ociperlimab (CHEMBL4650411) is a phase-3 clinical-stage antibody; indicated across 9 conditions including neoplasm and non-small cell lung carcinoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Indications: 9 conditions
- Clinical trials: 13
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4650411 |
| Name | Ociperlimab |
| Type | Antibody |
| Max phase | 3 |
Also known as: Bgb-a1217, BGB-A1217, BGBA-1217, BGBA1217, Ociperlimab, OCIPERLIMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| neoplasm | 3 | MONDO:0005070 | EFO:0000616 |
| non-small cell lung carcinoma | 3 | MONDO:0005233 | EFO:0003060 |
| esophageal squamous cell carcinoma | 2 | MONDO:0005580 | EFO:0005922 |
| hepatocellular carcinoma | 2 | MONDO:0007256 | EFO:0000182 |
| small cell lung carcinoma | 2 | MONDO:0008433 | EFO:0000702 |
| breast neoplasm | 2 | MONDO:0021100 | MONDO:0007254 |
| diffuse large B-cell lymphoma | 1 | MONDO:0018905 | EFO:0000403 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 13.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 7 |
| PHASE3 | 4 |
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04164199 | PHASE3 | ACTIVE_NOT_RECRUITING | Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies |
| NCT04746924 | PHASE3 | TERMINATED | A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer |
| NCT04866017 | PHASE3 | TERMINATED | A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer |
| NCT05791097 | PHASE3 | WITHDRAWN | Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC. |
| NCT04693234 | PHASE2 | COMPLETED | AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer |
| NCT04732494 | PHASE2 | COMPLETED | Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma |
| NCT04948697 | PHASE2 | COMPLETED | A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC |
| NCT04952597 | PHASE2 | COMPLETED | Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer |
| NCT05014815 | PHASE2 | COMPLETED | Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer |
| NCT05267054 | PHASE1/PHASE2 | COMPLETED | Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab |
| NCT05577702 | PHASE2 | COMPLETED | Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer |
| NCT05809895 | PHASE2 | WITHDRAWN | Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer |
| NCT04047862 | PHASE1 | COMPLETED | Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: neoplasm, non-small cell lung carcinoma